-
Dopamine D1-D3 Receptor Heteromer as a New Target for Parkinson's Disease
… can be involved in the pathogenesis of L-dopa-induced dyskinesia in patients with Parkinson’s disease. Project … in Parkinson’s disease and, particularly for L-DOPA-induced dyskinesia. The discovery of compounds able to alter D1-D3 …
-
Six-month Oral Toxicity Study of the Accordion Pill™ of Carbidopa/Levodopa
… without increasing or with decreasing the "on" time of dyskinesia and with fewer levodopa doses per day. These … October 2016 … Dyskinesia … Clinical Trial … Israel … Research Grant … …
-
SHP-2 Phosphatase: A New Pharmacological Target for Parkinson's Disease?
… disease, induces severe involuntary movements termed dyskinesias. The development of these motor dysfunctions has … of SHP-2 expression alleviates levodopa-induced dyskinesias in an experimental model of Parkinson’s disease. …
-
Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease
… to induce a loss of muscle control (levodopa-induced dyskinesia or LID) that almost always besets Parkinson’s … We also found that HE3286 decreased levodopa-induced dyskinesia better than placebo and better than amanatidine, …
-
Susceptibility Genes for Antipsychotic-induced Extrapyramidal Symptoms as Modifier Genes in Parkinson's Disease and L-dopa Treatment Response
… clinically similar to PD, and chronic, late onset, tardive dyskinesia (TD), which is clinically similar to L-dopa induced dyskinesia (LID). Besides demographic and clinical risk …
-
Predicting the Efficacious Dose of the Selective 5-HT1A Agonist NLX-112
… underlies the development of troubling levodopa-induced dyskinesia that affects many PD patients. One strategy is to … dopamine release and completely abolished the dyskinesia-like symptoms observed in models of PD. These …